Why Japan for Drug Development Vol.2 Taking the Next Steps with Your Drug in Japan
The webinar, co‑hosted by NIK Biotechnology and sponsored by Nexera, focused on the latest PMDA initiatives that make Japan an increasingly attractive market for drug developers. Speakers highlighted Japan’s position as the world’s third‑largest pharmaceutical market, the transparency of PMDA’s review schedules, and the rapid, standardized drug‑price listing that follows approval. Key policy updates included the 2023 administrative notification stating that a dedicated Japanese phase‑I study is not required when safety and tolerability can be demonstrated from overseas data, and the allowance for approval based solely on pivotal foreign trials for orphan or high‑need therapies. PMDA also announced revisions to its conditional‑approval framework and an extension of re‑examination periods for pediatric and rare‑disease drugs to curb the historic drug‑lag. Dr. Yasu Fujiwara emphasized the market’s size and predictability, while Dr. Akiho Ishiguro explained the new Washington DC office’s role in providing English‑language consultation and direct liaison with the US FDA and venture firms. Early‑consideration guidance documents, such as those on externally controlled trials, illustrate PMDA’s push toward more flexible, science‑based evaluation pathways. For multinational sponsors, these developments mean faster entry timelines, clearer regulatory expectations, and a dedicated channel for real‑time dialogue with Japanese authorities, potentially accelerating patient access to innovative therapies in Japan.
(Review) Regulation and Review Process of OTC Drugs in Japan - PMDA-ATC Learning Viedos
The video outlines Japan’s regulatory framework for over‑the‑counter (OTC) medicines, emphasizing self‑medication as a policy response to an aging population and fiscal pressures on universal health coverage. Over the past five years, roughly 600‑700 OTC applications are filed annually, with a...
(Review) Orphan Drug Designation System in Japan - PMDA-ATC Learning Videos
The video explains Japan's orphan drug designation system, governed by the PMD Act, its enforcement regulations, and a specific notification. It outlines the three eligibility criteria—patient population, medical need, and development feasibility—that a drug must meet to qualify. A drug qualifies...
PMDA Washington D.C. Office Initiatives
The video outlines the launch of the PMDA Washington DC office, the agency’s first permanent base in the United States, under its 2024‑2029 mid‑term plan. Located near the White House, the office serves as a physical gateway for Japanese regulators...
Abridged Regulatory Pathways
The video explains the concept of bridged regulatory pathways, a reliance‑based model that lets national regulatory authorities (NRAs) base decisions on assessments performed by a reference agency such as Japan’s PMDA. The World Health Organization defines reliance as a means...
Regulatory Evolution to Expedite Drug Development in Japan: A PMDA Initiatives
The video outlines PMDA’s latest regulatory reforms aimed at accelerating drug development in Japan. Since its 2004 inception, the agency has cut review cycles dramatically, yet a growing “drug loss” problem persists as 35% of drugs approved in the United...